Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy

El‐Jawahri, Areej; Abel, Gregory A.; Traeger, Lara; Waldman, Lauren; Markovitz, Netana H.; VanDusen, Harry; Fathi, Amir T.; Steensma, David P.; LeBlanc, Thomas W.; Horick, Nora; DeAngelo, Daniel J.; Wadleigh, Martha; Hobbs, Gabriela; Foster, Jared C.; Brunner, Andrew M.; Amrein, Philip C.; Stone, Richard; Temel, Jennifer S.; Greer, Joseph A.

doi:10.1038/s41375-019-0449-1

Cited by 52 publications

(53 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The importance of anxiety and depression have been increasingly implicated in leukemia patients, which not only drives increasing attention to the mental health need but also leads to a paradigm shift in the management of leukemia. [6,7,15] However, correlations of anxiety and depression with clinical characteristics and survival profiles in AML patients have rarely been studied. In this study, we investigated the prevalence and severity of anxiety and depression in AML patients, and the correlations of anxiety, and also depression with clinical characteristics and survival profiles in AML patients, which elucidated that: anxiety and depression were much more prevalent and severe in AML patients compared with HCs; anxiety and depression predicted worse EFS and OS in AML patients.…”

Section: Discussionmentioning

confidence: 99%

“…The substantial mental distress caused by disease burden (such as estimated poor prognosis) has resulted in an increasing prevalence of psychiatric disorders in AML patients with anxiety and depression being the most frequent disorders. [6,7] In fact, in patients with other cancers, anxiety and depression not only present with a pejorative effect on the quality of life, but also have a damaging effect on the treatment efficacy and survival profiles in patients with various cancers, such as nonsmall lung cancer and head and neck cancer. [8–10] Also, anxiety and depression have been reported to have prognostic value in leukemia patients as well; for instance, in chronic leukemia patients, anxiety and depression are correlated with tyrosine kinase inhibitor discontinuation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients

Ding¹,

Wang²,

et al. 2019

Medicine

View full text Add to dashboard Cite

This study aimed to investigate the prevalence/severity of anxiety and depression, and also their correlations with clinical characteristics and survival profiles in acute myeloid leukemia (AML) patients.In all, 208 AML patients and 200 age and sex-matched healthy controls (HCs) were recruited in this study. Anxiety and depression were assessed by the Hospital Anxiety and Depression Scale (HADS) in AML patients before initiating therapy and in HCs after being enrolled. Treatment response was assessed, and event-free survival (EFS), and also the overall survival (OS) were calculated.The HADS-anxiety score (P < .001), anxiety prevalence (P < .001), and anxiety severity (P < .001) were increased in AML patients than those in HCs. The HADS-depression score (P < .001), depression prevalence (P < .001), and also depression severity (P < .001) were higher in AML patients compared with HCs. No correlation of anxiety or depression with clinical characteristics was found in AML patients (all P > .05). Moreover, the anxiety (P = .178) and depression (P = .512) rates were similar between complete remission (CR) patients and non-CR patients. Additionally, the EFS was worse in anxiety patients compared with nonanxiety patients (P = .013). The OS was shorter in anxiety patients compared with nonanxiety patients (P = .015) and was also worse in depression patients compared with nondepression patients (P = .007).Anxiety and depression are much more frequent and severe in AML patients compared to HCs, and both of them predict unfavorable survival profiles in AML patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients

Ding¹,

Wang²,

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…Although it is often assumed patients given less intense induction would have superior QOL, El‐Jawhari et al analyzing QOL, anxiety, and depression in patients ≥60 during the first 24 weeks following initiation of remission induction therapy found that QOL and anxiety generally improved (depression stayed the same) regardless of whether intensive (anthracycline+ cytarabine) or less intense (HMA) induction was given 55 …”

Section: Treatmentmentioning

confidence: 99%

Acute myeloid leukemia: 2021 update on risk‐stratification and management

Estey

2020

American J Hematol

115

View full text Add to dashboard Cite

Management of AML involves choosing between purely palliative care, standard therapy and investigational therapy ("clinical trial"). Even most older patients likely benefit from treatment. Based on randomized trials CPX 351, midostaurin, gemtuzumab ozogamicin, and venetoclax, the latter three when combined with other drugs, should now be considered standard therapy. Knowledge of the likely results with these therapies is essential in deciding whether to recommend them or participate in a clinical trial, possibly including these drugs. Hence here, in the con

show abstract

“…Previous studies in AML have shown improvement of QoL over time and independent of age . Also, El‐Jawahri et al found that QoL and symptoms of depression and anxiety were equally good in patients >60 years receiving intensive chemotherapy or hypomethylating agents for newly diagnosed AML.…”

Section: Discussionmentioning

confidence: 96%

“…Previous studies in AML have shown improvement of QoL over time and independent of age. 35,36 Also, El-Jawahri et al 37 found…”

Section: Overall Survivalmentioning

confidence: 98%

Introducing patient‐reported outcome in the acute leukemia quality registries in Sweden

Lennmyr

Karlsson

Abrahamsson

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractObjectives: The use of patient-reported outcome (PRO) measured outside clinical trials is not well defined. We report the first analysis of the prospective PRO study within the Swedish acute myeloid leukemia (AML) and the acute lymphoblastic leukemia (ALL) registries. Methods: PRO was requested 6 months after diagnosis. The EORTC Quality of life Questionnaire Core 30-item, the Patient Health Questionnaire-8 (PHQ-8), and questions from a Swedish National Cancer Questionnaire were used.Results: An invitation letter was sent to 398 patients; 255 (64%) responded, 60% web-based, and 40% on paper. The ALL cohort had lower physical, role and social functioning, higher symptom burden, and more financial difficulties compared to the AML cohort. A PHQ-8 score ≥ 10p, which indicates depression, was reported in 18% of the patients; 33% of these patients reported being prescribed antidepressants. The patients' overall experience of care was satisfying, but more psychological and practical support was desired. There was no difference in survival between patients who reported their PRO and those who did not. Follow-up at 2 and 4 years is ongoing.Conclusions: PRO collected in a registry-based setting is feasible, but the selection of time points and questionnaires are delicate in a diverse patient population.

show abstract

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy

Cited by 52 publications

References 34 publications

Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients

Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients

Acute myeloid leukemia: 2021 update on risk‐stratification and management

Introducing patient‐reported outcome in the acute leukemia quality registries in Sweden

Contact Info

Product

Resources

About